Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsOscar Health GLP-1 Coverage Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentOscar HealthPolicy PG152

    Antidiabetic Agents - Glucagon-like Peptide-1 (GLP-1) Receptor Agonists

    Customize your policy alerts

    Sign up for Oscar Health Policy PG152 alerts

    Get alerted when Policy PG152 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and prior authorization for GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists used to treat type 2 diabetes mellitus, including initial and continued therapy.

    Policy Summary
    PayerOscar Health
    PolicyAntidiabetic Agents - GLP-1 Receptor Agonists
    Policy CodePolicy PG152
    Change TypeNo material change
    Effective DateN/A
    Last ReviewNov 2, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing that preferred medication(s) were ineffective or cannot be used before requesting non-preferred therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥6.5%Qualifying HbA1c diagnostic threshold
    1,500 mg/dayMinimum metformin trial
    12 monthsMaximum approval duration
    Type 1 diabetesUnproven indication
    4

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Separate policies for other indications

    General Coverage Criteria

    General Medical Necessity Criteria

    Covered when ALL of the following general medical necessity criteria are met:

    General medical necessity

    • The medication is age-appropriate for the member under its FDA-approved indication.

      The member must be at least 10 years old for Bydureon BCise, Mounjaro, Trulicity, or Victoza; the member must be at least 18 years old for other GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists.

    • The member is not receiving the requested medication in combination with a DPP-4 inhibitor or DPP-4 antidiabetic combination.
    • The requested medication will not be used concomitantly with another GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist.
    • The requested product is prescribed at a dose and frequency within FDA-approved labeling or supported by compendia or evidence-based published dosing guidelines for the requested indication.
    • The member meets the applicable initial or subsequent clinical review criteria.

    Initial Therapy - Type 2 Diabetes Mellitus

    Covered for initial therapy when ALL general criteria and the qualifying type 2 diabetes diagnostic criterion are met, plus ANY ONE treatment pathway:

    Initial type 2 diabetes therapy

    • The member meets all general medical necessity criteria.
    • ONE qualifying diagnostic criterion

      • Fasting plasma glucose is at least 126 mg/dL (7.0 mmol/L).≥126 mg/dL (≥7.0 mmol/L)
      • The 2-hour glucose tolerance test result is at least 200 mg/dL (11.1 mmol/L).≥200 mg/dL (≥11.1 mmol/L)
      • Hemoglobin A1c is at least 6.5% (48 mmol/mol).

    Continuation Therapy - Type 2 Diabetes Mellitus

    Covered for continuation when applicable general and initial criteria are met and at least ONE continuation outcome is documented:

    Continuation therapy

    • The member meets the applicable general medical necessity and initial clinical review criteria.
    • AT LEAST ONE continuation outcome

      • HbA1c has decreased since initiation of therapy, documented within the past 6 months.

        Document a reduction from the value at therapy initiation.

      • The member has attained the target HbA1c, such as less than 7%, or the individualized target determined by the treating provider.Example target: HbA1c <7%
      • Glycemic control has improved, demonstrated by improved fasting plasma glucose or achievement of another individualized glycemic target, such as average blood glucose, reduced preprandial or postprandial glucose, or time in range for members using continuous glucose monitoring.

    GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists are considered experimental, investigational, or unproven for type 1 diabetes mellitus, type 1.5 diabetes mellitus, or any other use outside the covered type 2 diabetes indication.

    This guideline addresses use for type 2 diabetes mellitus. Use for obesity or weight management, cardiovascular risk reduction, MASH, or obstructive sleep apnea is governed by separate Oscar Health policies, including PG070, PG194, PG255, and PG276, as applicable.

    Use of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists for type 1 diabetes mellitus is considered experimental, investigational, or unproven. These therapies have not been adequately studied in type 1 diabetes, and reported benefits have been modest while risks such as diabetic ketoacidosis and gastrointestinal adverse effects limit their use.

    Use of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists for type 1.5 diabetes mellitus is considered experimental, investigational, or unproven. Because type 1.5 diabetes is not recognized as a distinct classification by the American Diabetes Association, the prescriber must determine the member’s appropriate primary diabetes diagnosis.

    Use of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists for any other use not addressed by this guideline is considered experimental, investigational, or unproven.

    Concurrent treatment with a DPP-4 inhibitor or DPP-4 antidiabetic combination does not meet general medical necessity criteria. Concurrent use with another GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist is also excluded.

    Initial Therapy

    Initial Therapy

    Initial therapy is covered when ALL general medical necessity and diagnostic criteria are met, plus ANY ONE treatment pathway:

    Initial therapy

    • The member meets the general medical necessity criteria, including age-appropriate use, no prohibited concurrent incretin therapy, and dosing within FDA-approved labeling or supported evidence-based guidance.
    • ONE qualifying type 2 diabetes diagnostic criterion

      • Fasting plasma glucose is at least 126 mg/dL (7.0 mmol/L).≥126 mg/dL (≥7.0 mmol/L)
      • The 2-hour glucose tolerance test result is at least 200 mg/dL (11.1 mmol/L).≥200 mg/dL (≥11.1 mmol/L)

    Continuation and Reauthorization

    Subsequent/Continuation Therapy

    Continuation therapy is covered when ALL applicable general and initial criteria are met and ANY ONE continuation outcome is documented:

    Subsequent or continuation therapy

    • The member continues to meet the applicable general medical necessity and initial clinical review criteria.
    • ONE continuation outcome

      • HbA1c has decreased since initiation of therapy, documented within the past 6 months.
      • The member has attained an HbA1c target, such as less than 7%, or an individualized target determined by the treating provider.Example target: HbA1c <7%

    Diagnostic and Clinical Thresholds

    Fasting plasma glucose
    Diagnostic testFasting plasma glucose
    Qualifying value≥126 mg/dL
    SI equivalent≥7.0 mmol/L
    2-hour glucose tolerance test
    Diagnostic test2-hour glucose tolerance test
    Qualifying value≥200 mg/dL
    SI equivalent≥11.1 mmol/L

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization and Non-Formulary Review

    Prior authorization is required for GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists used for type 2 diabetes mellitus. Non-formulary requests are subject to the Plan's Non-Formulary Products Criteria (PG069).

    • Coverage under this guideline is limited to type 2 diabetes mellitus; other indications are managed under separate guidelines.
    Prior Authorization

    Initial Authorization Requirements

    Initial authorization requires the member to meet all applicable general medical necessity criteria and the type 2 diabetes mellitus initial clinical review criteria.

    • The requested medication must be age-appropriate and prescribed at an FDA-approved, compendia-supported, or evidence-based dose and frequency.
    • The member must not use a GLP-1 or dual GIP/GLP-1 receptor agonist with a DPP-4 inhibitor or another GLP-1 or dual GIP/GLP-1 receptor agonist.
    • The member must have qualifying type 2 diabetes diagnostic results and meet at least one applicable initial-therapy pathway.

    Prerequisite Medication Requirements

    StepRequirementAdditional review
    1The member must be unable to use or must have tried and failed preferred medication(s) before coverage of a non-preferred medication.Non-formulary medication requests are subject to the Non-Formulary Products Criteria (PG069).
    StepRequirementDuration
    1For the metformin pathway to initial GLP-1 or dual GIP/GLP-1 therapy, the member must be unable to use or must have tried and failed metformin at the minimum effective dose.Metformin 1,500 mg daily for at least 90 days.

    Clinical Background

    GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists are incretin-based therapies that improve glucose-dependent insulin secretion and suppress glucagon secretion. They also slow gastric emptying and promote satiety, supporting improved glycemic control when used primarily with diet and exercise in type 2 diabetes mellitus. Some agents have demonstrated cardiovascular or chronic kidney disease benefits.

    Policy Definitions

    Atherosclerotic Cardiovascular Disease (ASCVD)
    DefinitionAtherosclerotic-origin acute coronary syndrome or a history of myocardial infarction
    Coronary conditionsStable or unstable angina, or coronary or other arterial revascularization
    Other qualifying conditionsStroke, transient ischemic attack, or peripheral arterial disease, including aortic aneurysm
    Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
    Drug classOral antidiabetic drugs used primarily to manage type 2 diabetes mellitus
    MechanismBlock the DPP-4 enzyme, which degrades the incretin hormones GLP-1 and GIP
    Policy Summary
    PayerOscar Health
    PolicyAntidiabetic Agents - GLP-1 Receptor Agonists
    Policy CodePolicy PG152
    Change TypeNo material change
    Effective DateN/A
    Last ReviewNov 2, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing that preferred medication(s) were ineffective or cannot be used before requesting non-preferred therapy.
    SourceLink
    On This Page
    General Coverage CriteriaInitial TherapyContinuation and ReauthorizationDiagnostic and Clinical ThresholdsAuthorization, Documentation, and Denial RisksPrerequisite Medication RequirementsClinical BackgroundPolicy Definitions
    ≥6.5% (≥48 mmol/mol)
  1. Random plasma glucose is at least 200 mg/dL (11.1 mmol/L).≥200 mg/dL (≥11.1 mmol/L)
  2. ONE treatment pathway

    • The member is unable to use, or has tried and failed, metformin at a minimum effective dose of 1,500 mg daily for at least 90 days.1,500 mg daily for at least 90 days
    • The member requires combination therapy to achieve glycemic control and has an HbA1c of at least 7.5%.HbA1c ≥7.5%
    • The member has established ASCVD or at least two cardiovascular risk factors and the request is for Victoza, Mounjaro, Ozempic injection, Rybelsus/Ozempic pill, or Trulicity.
    • The member has CKD with an eGFR of at least 15 mL/min/1.73 m² and the request is for Victoza, Ozempic injection, or Trulicity.eGFR ≥15 mL/min/1.73 m²
  3. The member has established ASCVD, multiple cardiovascular risk factors, or CKD and is receiving an eligible agent with proven benefit in these conditions.

    Eligible agents are Victoza, Mounjaro, Ozempic injection, Rybelsus/Ozempic pill, and Trulicity.

  4. Hemoglobin A1c is at least 6.5% (48 mmol/mol).≥6.5% (≥48 mmol/mol)
  5. Random plasma glucose is at least 200 mg/dL (11.1 mmol/L).≥200 mg/dL (≥11.1 mmol/L)
  6. ONE treatment pathway

    • The member is unable to use, or has tried and failed, metformin at a minimum effective dose of 1,500 mg daily for at least 90 days.1,500 mg daily for at least 90 days
    • The member requires combination therapy to achieve glycemic control and has an HbA1c of at least 7.5%.HbA1c ≥7.5%
    • The member has established ASCVD or at least two cardiovascular risk factors and requests Victoza, Mounjaro, Ozempic injection, Rybelsus/Ozempic pill, or Trulicity.
    • The member has CKD with an eGFR of at least 15 mL/min/1.73 m² and requests Victoza, Ozempic injection, or Trulicity.eGFR ≥15 mL/min/1.73 m²
  7. Glycemic control has improved through fasting plasma glucose or another individualized glycemic target, including average blood glucose, preprandial or postprandial glucose, or time in range for members using continuous glucose monitoring.
  8. The member has established ASCVD, multiple cardiovascular risk factors, or CKD and is receiving an eligible GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist with proven benefit in these conditions.

    Eligible agents are Victoza, Mounjaro, Ozempic injection, Rybelsus/Ozempic pill, and Trulicity.

  9. Reauthorization

    Reauthorization is covered when ALL applicable reauthorization requirements are met:

    • The member continues to meet the applicable general medical necessity criteria.
    • ONE documented basis for continued therapy

      • HbA1c has decreased since initiation of therapy, documented within the past 6 months.
      • The member has attained the target HbA1c, such as less than 7%, or an individualized target determined by the treating provider.Example target: HbA1c <7%
      • Glycemic control has improved through fasting plasma glucose or another individualized glycemic target.
      • The member has established ASCVD, multiple cardiovascular risk factors, or CKD and the requested agent is Victoza, Mounjaro, Ozempic injection, Rybelsus/Ozempic pill, or Trulicity.

    Reauthorization Approval

    When the applicable reauthorization criteria are met:

    Reauthorization approval

    • The applicable reauthorization criteria are met.

      The requested drug will be approved for up to 12 months.

    Hemoglobin A1c threshold
    Diagnostic testHemoglobin A1c (HbA1c)
    Qualifying value≥6.5%
    SI equivalent≥48 mmol/mol
    Random plasma glucose
    Diagnostic testRandom plasma glucose
    Qualifying value≥200 mg/dL
    SI equivalent≥11.1 mmol/L
    Combination-therapy HbA1c threshold
    Treatment pathwayCombination therapy to achieve glycemic control
    Required HbA1c≥7.5%
    Additional requirementThe member must require combination therapy to achieve glycemic control
    Chronic kidney disease eGFR threshold
    ConditionChronic kidney disease (CKD)
    Qualifying eGFR≥15 mL/min/1.73 m²
    Eligible agentsVictoza, Ozempic injection, or Trulicity
    Prior Authorization

    Reauthorization Requirements

    Reauthorization requires continued satisfaction of applicable general and initial clinical review criteria, plus documented treatment response or a qualifying clinical outcome.

    • Document a reduction in HbA1c within the past 6 months, attainment of an individualized target HbA1c, or improvement in glycemic control.
    • Qualifying improvement may include lower fasting plasma glucose or achievement of other individual glycemic targets, such as improved average glucose, preprandial or postprandial glucose, or continuous glucose monitor time in range.
    • Established ASCVD, multiple cardiovascular risk factors, or CKD may qualify when the requested agent is one of the agents identified in the policy as having proven benefit.
    Prior Authorization

    Covered Indication for Authorization

    Prior authorization and reauthorization under this guideline apply to covered use of the requested GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist for type 2 diabetes mellitus.

    • Requests for weight management, cardiovascular risk reduction, MASH, or obstructive sleep apnea must be reviewed under the applicable separate Oscar guideline.

    Unsupported block type: billing_rule

    Step Therapy

    Preferred Medication Prerequisite

    Before requesting coverage for a non-preferred medication, document that the member is unable to use the preferred medication or has tried and failed the preferred medication(s).

    • Non-formulary medication requests remain subject to the Non-Formulary Products Criteria (PG069).
    • Include the reason the preferred medication cannot be used or the clinical outcome demonstrating failure.
    Documentation Required

    Metformin Trial or Intolerance

    For the standard initial-therapy pathway, document inability to use metformin or a trial and failure of metformin at a minimum effective dose of 1,500 mg daily for at least 90 days.

    • An alternative pathway may apply when combination therapy is required to achieve glycemic control and HbA1c is at least 7.5%.
    • Other policy pathways may apply for established ASCVD, multiple cardiovascular risk factors, or CKD when the requested product is an identified qualifying agent.
    Documentation Required

    Clinical and Formulary Trial Documentation

    Submit documentation supporting the diagnosis, relevant clinical criteria, and any required formulary trials or failures.

    • Up-to-date chart notes, relevant test results, and/or relevant imaging reports may support the diagnosis and medical necessity.
    • Prescription claims records and/or prescription receipts may support prior trials of formulary alternatives.
    Documentation Required

    Initial Therapy Clinical Documentation

    For initial therapy, submit the qualifying diabetes diagnostic result and documentation of the applicable treatment pathway.

    • Acceptable diagnostic thresholds include fasting plasma glucose ≥126 mg/dL, 2-hour glucose tolerance test ≥200 mg/dL, HbA1c ≥6.5%, or random plasma glucose ≥200 mg/dL.
    • Absent unequivocal hyperglycemia or classic hyperglycemic symptoms, diagnosis confirmation generally requires two abnormal results from different tests or the same test at two different time points, consistent with the policy note.
    • Document metformin trial or inability to use metformin, qualifying combination-therapy need and HbA1c ≥7.5%, or the applicable ASCVD, cardiovascular-risk-factor, or CKD pathway.
    Documentation Required

    Continuation Response Documentation

    For continuation requests, provide a recent measure of glycemic control and evidence that therapy is working or that a qualifying outcome supports continuation.

    • Submit an HbA1c reduction documented within the past 6 months, attainment of a target HbA1c, or documented improvement in glycemic control.
    • Include the relevant fasting glucose, individual glycemic target, or continuous glucose monitor measure when used to demonstrate response.
    Denial Risk

    General Medical Necessity Denial Risk

    Failure to satisfy general medical necessity requirements may result in denial even when the member has type 2 diabetes.

    • The medication must be age-appropriate: Bydureon BCise, Mounjaro, Trulicity, and Victoza require age ≥10; other GLP-1 and dual GIP/GLP-1 products require age ≥18.
    • Do not use the requested product with a DPP-4 inhibitor or another GLP-1 or dual GIP/GLP-1 receptor agonist.
    • The dose and frequency must be within FDA-approved labeling or supported by compendia or evidence-based published dosing guidelines.
    Denial Risk

    Initial Type 2 Diabetes Criteria Not Met

    Initial coverage may be denied when the member lacks a qualifying type 2 diabetes diagnosis or does not meet an applicable initial-therapy pathway.

    • Document at least one qualifying diagnostic result and, when applicable, the required confirmation of diagnosis.
    • Document metformin intolerance or failure, qualifying combination-therapy need with HbA1c ≥7.5%, or the applicable ASCVD, cardiovascular-risk-factor, or CKD criteria.
    Denial Risk

    Insufficient Response or Continuation Evidence

    Reauthorization may be denied when the required glycemic response, target attainment, improvement, or qualifying continuation evidence is not documented.

    • A recent HbA1c or other glycemic-control measure must support the continuation request.
    • Documentation must show HbA1c reduction, attainment of a member-specific target, improvement in glycemic control, or a qualifying ASCVD, cardiovascular-risk-factor, or CKD-based outcome.
    Denial Risk

    Indication Outside This Policy

    This policy covers GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists for type 2 diabetes mellitus only. Type 1 diabetes, type 1.5 diabetes, weight management, cardiovascular risk reduction, and other indications are outside this policy's covered indication.

    • Review weight management requests under Weight Loss Agents (PG070).
    • Review Wegovy requests for cardiovascular risk reduction or MASH under PG194.
    • Review Zepbound requests for obstructive sleep apnea under PG255 or PG276 for New York members.
    Denial Risk

    Noncovered or Unproven Indication

    Use for type 1 diabetes, type 1.5 diabetes, or any other indication is considered experimental, investigational, or unproven under this guideline.

    • GLP-1 and dual GIP/GLP-1 receptor agonists are not adequately established for type 1 diabetes under this policy.
    • The ADA does not recognize type 1.5 diabetes as a designation; the prescriber must determine the member's appropriate primary diabetes diagnosis.
    Examples
    Alogliptin, saxagliptin, sitagliptin, linagliptin, and related combination products
    Incretin Mimetics
    DefinitionMedications that imitate the function of incretins, natural hormones that help lower post-meal blood sugar
    Digestive and hepatic effectsSlow digestion and prevent the liver from making too much glucose
    Pancreatic effectHelp the pancreas produce more insulin when needed
    Type 2 Diabetes
    DefinitionA metabolic disorder characterized by insufficient insulin production or insulin resistance in body cells
    Relative prevalenceMore common than type 1 diabetes
    Management contextOften managed through lifestyle changes, non-insulin medications, and, if necessary, insulin injections
    Hemoglobin A1c (HbA1c)
    TestBlood test measuring average blood glucose levels
    Measurement periodApproximately the past 2 to 3 months
    Other namesA1C or glycosylated hemoglobin test
    Type 1.5 diabetes mellitus
    DesignationA proposed diabetes designation
    Clinical featuresA member may have features of both type 1 diabetes and type 2 diabetes
    Classification statusThe American Diabetes Association does not currently recognize type 1.5 diabetes as a distinct classification
    GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists
    Medication groupIncretin mimetics
    Included classGLP-1 receptor agonists
    Dual classDual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists